VitaDisc
Financiado
A novel non-invasive therapy based on injectable viscous gel for restoring the n...
A novel non-invasive therapy based on injectable viscous gel for restoring the natural biomechanics of the spine and relieving patients from pain
Over 400 million people globally suffer from back pain. Disc degeneration disease is the prevalent cause of back pain and it is responsible for high social and economic costs. Current treatments are only symptomatic (physiotherapy...
Over 400 million people globally suffer from back pain. Disc degeneration disease is the prevalent cause of back pain and it is responsible for high social and economic costs. Current treatments are only symptomatic (physiotherapy, pain management or surgery), but they do not regenerate the disc and its function.
At NC Biomatrix, we have developed VitaDisc, the first non-invasive early restorative treatment for disc degeneration that has the power to revolutionise the orthopaedics market. It is an acellular porcine-derived injectable biomatrix that restores disc height, provides optimal support to regenerate the disc, and aids in restoring healthy spinal biomechanics. Its mode of action is fully mechanical, and it can be easily administered in an outpatient setting, giving it a unique market advantage.
Our biomatrix platform technology is readily scalable and provides a pipeline of further products for unmet needs in orthopaedic treatments, such as early-stage knee joint arthritis.
ver más
Duración del proyecto: 27 meses
Fecha Inicio: 2023-06-23
Fecha Fin: 2025-09-30
Fecha Fin: 2025-09-30
Línea de financiación: concedida
El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-06-23
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
HORIZON-EIC-2022-ACCELERATOROPEN-01:
EIC Accelerator Open
Cerrada
hace 1 año
Presupuesto
El presupuesto total del proyecto asciende a
5M€
Líder del proyecto
NC BIOMATRIX BV
No se ha especificado una descripción o un objeto social para esta compañía.
